RadNet (RDNT)
(Delayed Data from NSDQ)
$68.58 USD
+3.59 (5.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $68.61 +0.03 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.58 USD
+3.59 (5.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $68.61 +0.03 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth C Momentum B VGM
Zacks News
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RadNet (RDNT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 200% and 1.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 1.26% and 1.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Stocks to Watch From a Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic-induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.
RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -650% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -31.58% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Oak Street Health, Inc. (OSH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of -5.08% and 2.23%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 23.53% and 1.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 0.86% and 0.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights DaVita, RadNet and U.S. Physical Therapy
by Zacks Equity Research
DaVita, RadNet and U.S. Physical Therapy are included in this blog.
3 Stocks to Bank on the Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, RDNT and USPH are well-poised to gain from the prospects.
RadNet (RDNT) Q3 Earnings Top Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 5.00% and -2.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
RadNet (RDNT) closed at $31.96 in the latest trading session, marking a -0.87% move from the prior day.
RadNet (RDNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Encompass Health, RadNet, U.S. Physical Therapy and Quest Diagnostics
3 Top Stocks From the Buoyant Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. EHC, RDNT and USPH are well-poised to gain from the prospects.
New Strong Buy Stocks for September 20th
by Zacks Equity Research
RDNT, ACH, FNF, MG, and TPR have been added to the Zacks Rank #1 (Strong Buy) List on September 20, 2021.
New Strong Buy Stocks for September 14th
by Zacks Equity Research
CPRI, MAN, RDNT, HSII, and OLN have been added to the Zacks Rank #1 (Strong Buy) List on September 14, 2021.
New Strong Buy Stocks for September 1st
by Zacks Equity Research
BBY, CNHI, RDNT, SALM, and TOL have been added to the Zacks Rank #1 (Strong Buy) List on September 1, 2021.
New Strong Buy Stocks for August 30th
by Zacks Equity Research
DSKE, HNGR, GPS, SCSC, and RDNT have been added to the Zacks Rank #1 (Strong Buy) List on August 30, 2021
Zacks.com featured highlights include: NBT Bancorp, Bio-Rad Laboratories, RadNet, Arbor Realty Trust and Cathay General Bancorp
by Zacks Equity Research
Zacks.com featured highlights include: NBT Bancorp, Bio-Rad Laboratories, RadNet, Arbor Realty Trust and Cathay General Bancorp
New Analyst Coverage Puts Spotlight on These 5 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like NBTB, BIO, RDNT, ABR and CATY.
New Strong Buy Stocks for August 19th
by Zacks Equity Research
AOSL, CCS, GMS, RDNT, and SALM have been added to the Zacks Rank #1 (Strong Buy) List on August 19, 2021.
RadNet (RDNT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 92.86% and 2.18%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.